NCCN Survey Persistent Cancer Drug Shortages
Analysis based on 6 articles · First reported Sep 10, 2026 · Last updated Sep 14, 2026
The persistent shortages of low-margin generic oncology drugs highlight fragile sterile-injectable supply chains and could weigh on hospital and cancer-center operating costs, treatment capacity, and margins. Policy responses such as the FDA import relaxation from India may modestly ease near-term supply, but the structural lack of manufacturing incentives keeps downside risk for generic drugmakers and healthcare providers in focus.
The National Comprehensive Cancer Network published updated survey data on generic cancer medication shortages in the United States, based on responses from pharmacy directors and clinical leadership at its member institutions collected in late August 2026. All responding cancer centers reported a shortage of at least one anti-cancer agent, with more than 20% short of five or more medications. Ifosfamide was in short supply at 94% of centers, carboplatin at 71%, cisplatin at 16%, and the immunotherapy Bacillus Calmette-Guerin at more than half. NCCN has tracked the issue since June 2023, and 96% of pharmacy directors said national or state policies have not improved the situation. Centers have adopted mitigation strategies such as waste management, alternative regimens, and repeat prior authorizations, which delay care. The United States — Food and Drug Administration recently announced a temporary relaxation of import restrictions on supplies from India to help relieve the shortage. NCCN is part of the End Cancer Drug Shortages Coalition, which issued a May 2026 consensus statement urging supply-chain transparency, manufacturing incentives, and generic market stabilization. NCCN CEO Crystal S. Denlinger called the persistence of shortages disheartening, while chief medical officer Renuka Iyer noted the same drugs and issues recur. H. Lee Moffitt Cancer Center & Research Institute and Roswell Park Comprehensive Cancer Center were cited among members managing the problem, with Irvin Alfonso of Moffitt describing inventory and supplier strategies that left it with only one active critical shortage.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard